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and challengesIn patients with systolic heart failure and a wide QRS complex,
cardiac resynchronisation therapy (CRT) using left ventricular (LV)
pacing has been shown to enhance survival, reduce heart failure
hospitalisation and enhance exercise capacity in patients with all
classes of heart failure. The patient subsets most likely to beneﬁt
are those with class II–IV heart failure, LBBB and a QRS width
≥ 150 ms [1]. The application of CRT in patients with less wide
QRS, non-LBBB and atrial ﬁbrillation may be associated with less
beneﬁt. Coronary sinus placement of LV lead is the main channel
of CRT delivery. This can be challenging at times during implanta-
tion, and can restrict LV pacing to suboptimal site [2]. There are
post-implant complications such as LV lead dislodgment, dia-
phragmatic pacing and device infection.
A major limitation of CRT is the problem of non-responders,
which can be up to 30% of all indicated patients. The response rate
could be better when a QRS width ≥ 150 ms is used as an
indication for CRT. Apart from lead location and lack of enough
residual viable myocardium for resynchronisation, post-implant
programming may play a role in reducing non-responders. This
includes adjustment of atrioventricular [3] and interventricular
timing [4] and the use of fusion pacing [5,6].
The guideline for use of implantable cardioverter deﬁbrillator
(ICD) has not substantially changed since 2008 [7]. However, the
application of ICD especially for primary prevention therapy in the
Asia-Paciﬁc region has been limited not only by cost and reim-
bursement, but also because of controversy as to the application of
the primary prevention studies to the Asian populations [8–10].
Both appropriate and inappropriate ICD shocks carry adverse
prognosis [11], and device programming to minimise ICD therapies
and ablation of ventricular tachycardia have been used either
prophylactically or to treat VT/VF ICD storms. The most important
problem now encountered is deﬁbrillation lead failure by some
manufacturers. This has call forth the need to develop a system of
lead management that includes surveillance, programming and
lead extraction for ICD leads.
The Asia-Paciﬁc Heart Rhythm Society and the Japanese Heart
Rhythm Society have jointly produced a series of review and
original articles of these advances and challenges in CRT and ICD,
which will be presented in two separate issues. The editors are
conﬁdent that the well written articles will give the state of art
coverage on these important cardiac therapies.76/$ - see front matter & 2013 Japanese Heart Rhythm Society. Published by Els
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